Phase II Study of Modified Carboplatin Plus Weekly Nab-Paclitaxel in Elderly Patients with Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301
Eisaku Miyauchi(Tohoku University), Masakazu Ichinose(Osaki Citizen Hospital), Akira Inoue(Tohoku University Hospital), Toshiyuki Harada(Hokkaido hospital), Hiroshi Watanabe(Tohoku University), Makoto Maemondo(Miyagi Prefectural Hospital Organization), Kazuhiro Usui(Hokkaido University Hospital), Terufumi Kato(Taipei Veterans General Hospital), Toshiro Suzuki(Sendai Kousei Hospital), Yuka Fujita, Heisuke Saito(Iwate Medical University), Shunichi Sugawara(Sendai Kousei Hospital), Taku Nakagawa(Saint John's Health Center)
Cited by 16
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k